Objective: To study the treatmaient of non-small cell lung cancer, we established the HU-Prim allograft transplantation tumor model. Methods: The fresh tumor samples were transplanted in the right scapular subcutaneou...Objective: To study the treatmaient of non-small cell lung cancer, we established the HU-Prim allograft transplantation tumor model. Methods: The fresh tumor samples were transplanted in the right scapular subcutaneous layer of the severe combined immunodeficient Non-obese diabetic/severe combined immunodeficient(NOD/SCID) mice. The pathological features of the tumors were observed. Nonnecrotic tissue was inoculated subcutaneously into the right axillary. When the tumor in burdened rat grew approximately 100 mm3, according to the tumor size all the animals were divided into the following four groups, eight rats in each group: solvent control group, gefitinib group(100 mg/kg), erlotinib group(50 mg/kg), afatinib group(20 mg/kg). Aniamals were treated with drugs by intragastric(i.g.) administrated, once daily, for consecutively 14 days. Measure the tumor size 2-3 times every week. Results: Hu Prime1-NSCLC mutant sensitive xenograft model research data showed that reversible tyrosine kinase inhibitors gefitinib, erlotinib and irreversible tyrosine kinase inhibitor afatinib could effectively inhibit tumor growth in EGFR positive NSCLC allografts model. The pharmacodynamic activity of irreversible inhibitor was better than that of the reversible inhibitor. Specimens from clinical anthropogenic tumor retain characteristics of the human primary malignancy, histopathology, biological characteristics, and tumor markers, etc., which can more accurately reflect the characteristics of the tumor and the impact of interventions. Conclusion: The model is not only a good antitumor drug experimental platform, but also a new evaluation tool of individualized medication.展开更多
中医药在胃癌前病变(precancerous lesions of gastric cancer,PLGC)诊疗中发挥着重要作用,病证结合动物模型是进行PLGC相关实验研究的前提。文章从模型动物选择、胃癌前病变疾病模型和病证结合模型三方面,对近年来PLGC病证结合模型的...中医药在胃癌前病变(precancerous lesions of gastric cancer,PLGC)诊疗中发挥着重要作用,病证结合动物模型是进行PLGC相关实验研究的前提。文章从模型动物选择、胃癌前病变疾病模型和病证结合模型三方面,对近年来PLGC病证结合模型的制备方法进行了归纳分析,介绍了脾胃虚弱、胃阴不足、肝胃气滞、脾胃湿热和胃络瘀血5个常见PLGC病证结合模型的造模方法,并对当前模型制备中存在的问题提出了思考与展望。展开更多
基金National Natural Science Foundation of Tianjin,China(16JCYBJC27500)
文摘Objective: To study the treatmaient of non-small cell lung cancer, we established the HU-Prim allograft transplantation tumor model. Methods: The fresh tumor samples were transplanted in the right scapular subcutaneous layer of the severe combined immunodeficient Non-obese diabetic/severe combined immunodeficient(NOD/SCID) mice. The pathological features of the tumors were observed. Nonnecrotic tissue was inoculated subcutaneously into the right axillary. When the tumor in burdened rat grew approximately 100 mm3, according to the tumor size all the animals were divided into the following four groups, eight rats in each group: solvent control group, gefitinib group(100 mg/kg), erlotinib group(50 mg/kg), afatinib group(20 mg/kg). Aniamals were treated with drugs by intragastric(i.g.) administrated, once daily, for consecutively 14 days. Measure the tumor size 2-3 times every week. Results: Hu Prime1-NSCLC mutant sensitive xenograft model research data showed that reversible tyrosine kinase inhibitors gefitinib, erlotinib and irreversible tyrosine kinase inhibitor afatinib could effectively inhibit tumor growth in EGFR positive NSCLC allografts model. The pharmacodynamic activity of irreversible inhibitor was better than that of the reversible inhibitor. Specimens from clinical anthropogenic tumor retain characteristics of the human primary malignancy, histopathology, biological characteristics, and tumor markers, etc., which can more accurately reflect the characteristics of the tumor and the impact of interventions. Conclusion: The model is not only a good antitumor drug experimental platform, but also a new evaluation tool of individualized medication.
文摘中医药在胃癌前病变(precancerous lesions of gastric cancer,PLGC)诊疗中发挥着重要作用,病证结合动物模型是进行PLGC相关实验研究的前提。文章从模型动物选择、胃癌前病变疾病模型和病证结合模型三方面,对近年来PLGC病证结合模型的制备方法进行了归纳分析,介绍了脾胃虚弱、胃阴不足、肝胃气滞、脾胃湿热和胃络瘀血5个常见PLGC病证结合模型的造模方法,并对当前模型制备中存在的问题提出了思考与展望。